Table 2 Sub-clinical characteristics of influenza-infected children before treatment and treatment therapy.
Characteristic | Control group (N = 48) | Navax group (N = 44) | p value | |||
|---|---|---|---|---|---|---|
Total, n (%) | Min–max | Total, n (%) | Min–max | |||
Cardiopulmonary X-ray | ||||||
 Osler’s nodes | 32 (66.67) |  | 25 (56.82) |  | 0.33 | |
 Hyperinflation | 2 (4.17) |  | 0 (0.00) |  | 0.32 | |
 Osler’s nodes and hyperinflation | 3 (6.25) |  | 5 (11.36) |  | 0.39 | |
 Normal | 11 (22.92) |  | 14 (31.82) |  | 0.34 | |
Influenza positive | ||||||
 Rapid test | 48 (100) |  | 44 (100) |  | 0.97 | |
 Real-time PCR (Ct) | 48 (100) | 17.61–32.57 | 44 (100) | 15.55–29.00 | 0.97 | |
Hematology and biochemistry | ||||||
 Total white blood cells (G/L) |  | 2.86–18.20 |  | 5.71–25.46 |  | |
  < 6.0 | 4 (8.34) |  | 2 (4.55) |  | 0.47 | |
 6.0–10.0 (G/L) | 22 (45.83) |  | 27 (61.36) |  | 0.20 | |
  > 10.0 (G/L) | 22 (45.83) |  | 15 (34.09) |  | 0.19 | |
 Total red blood cells (T/L) |  | 3.64–6.13 |  | 3.66 – 6.14 |  | |
  < 3.0 (T/L) | 0 (0.00) |  | 0 (0.00) |  | –a | |
 3.0–5.0 (T/L) | 41 (85.42) |  | 34 (77.27) |  | 0.32 | |
  > 5.0 (T/L) | 7 (14.58) |  | 10 (22.73) |  | 0.32 | |
 Total platelet count (G/L) |  | 166–801 |  | 176–468 |  | |
  < 140 (G/L) | 0 (0.00) |  | 0 (0.00) |  | –a | |
 140–440 (G/L) | 43 (89.58) |  | 40 (90.91) |  | 0.83 | |
  > 440 (G/L) | 5 (10.42) |  | 4 (9.09) |  | 0.83 | |
 CRP (mg/L) |  | 0.08–111.46 |  | 0.46–41. 27 |  | |
  ≤ 6.0 | 33 (68.75) |  | 26 (59.09) |  | 0.34 | |
  > 6.0 | 15 (31.25) |  | 18 (40.91) |  | ||
Bacterial co-infection | 15 (31.25) | 22–30 | 22 (50.00) | 20–30 | 0.07 | |
 H. influenzae (HI) | 9 (18.75) |  | 13 (29.55) |  | 0.23 | |
 S. pneumoniae (SP) | 4 (8.33) |  | 7 (15.91) |  | 0.27 | |
 H. influenzae & S. pneumoniae (HI-SP) | 2 (4.17) |  | 0 (0.00) |  | 0.32 | |
 M. catarrhalis (MC) | 0 (0.00) |  | 2 (4.55) |  | 0.32 | |
Treatment therapy | ||||||
 Routine treatment | - Oral administrative drugs: antipyretic paracetamol (Efferegant); expectorant Carbocysteine (Carbothiol); antiviral Oseltamivir phosphate (Tamiflu); antibiotics e.g. cefotaxim (Goldcefo), Amoxicillin/acid clavulanic (Augmentin) based on the results of antibiotic susceptibility test - Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin inhaler) or budesonide (Pulmicort Respules) | |||||
 Nasal-spraying treatment | NaCl 0.9% | NaCl 0.9% plus B. subtilis and B. clausii at 5 billion CFU/5 mL (LiveSpo Navax) |  | |||
